Filing Overview
Issuer: I-MAB, a foreign private issuer with principal executive offices in Shanghai, China. The request metadata identifies Novabridge Biosciences, but the filing itself names I-MAB.
Form and period: Form 6-K covering the month of November 2021, filed November 2, 2021. Commission File Number 001-39173. The filing states that I-MAB files annual reports on Form 20-F.
Financial and Operating Metrics
The provided filing text contains no revenue, profit, cash flow, margin, debt, liquidity, operating, or other financial metrics.
Material Changes
The filing text does not describe material changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not include guidance, outlook, management commentary, risk disclosures, contingencies, or unusual items. It lists Exhibit 99.1 as a press release, but the press release content was not provided.
Investor Verification Checklist
- Verify the issuer identity, as the filing names I-MAB rather than Novabridge Biosciences.
- Obtain and review Exhibit 99.1, the referenced press release.
- Confirm whether the omitted exhibit contains financial results, business updates, guidance, risks, or other material disclosures.
- Review the complete Form 6-K and any related Form 20-F disclosures for financial and operating information.